The fall 2021 season has been marked by many exciting developments as a new cryptocurrency boom has taken shape. We’ve seen Bitcoin (CCC:BTC-USD) prices reach historic highs following the launch of the ProShares Bitcoin Strategy ETF (NYSE:BITO) and meme coin sensation Shiba Inu (CCC:SHIB-USD) surge past its predecessor Dogecoin (CCC:DOGE-USD) in prices, albeit briefly. Several of these surges…

October 2021 has marked several milestones in the history of crypto that have led to unprecedented gains within the sector. After the launch of the ProShares Bitcoin Strategy ETF (NYSE:BITO), Bitcoin (CCC:BTC-USD) saw its prices rise to all-time highs, creating a ripple effect that sent other major cryptos up as well. While Bitcoin prices would…

Home / Today’s Market / BTCR ETF: 10 Things to Know as the Volt Equity Bitcoin ETF Starts Trading Volt’s Bitcoin-related ETF is debuting on the New York Stock Exchange today By Brenden Rearick, InvestorPlace Assistant News Writer Oct 28, 2021, 12:21 pm EDT October 28, 2021 Bitcoin (CCC:BTC-USD) exchange-traded funds (ETFs) are one of…

Home / Today’s Market / VanEck Bitcoin ETF: 10 Things to Know as the Cheaper XBTF ETF Preps for Trading VanEck’s Bitcoin ETF is competing with its peers thanks to lower fees By Brenden Rearick, InvestorPlace Assistant News Writer Oct 26, 2021, 11:41 am EDT October 26, 2021 Crypto trading has made a quasi-debut on…

As the price of Bitcoin (CCC:BTC-USD) rallies to new all-time highs, Ethereum (CCC:ETH-USD) appears to have been left behind. Source: Filippo Ronca Cavalcanti / Shutterstock.com The launch this week of ProShares Bitcoin Strategy exchange traded fund (NYSE:BITO), the first full-fledged cryptocurrency ETF offered in the U.S., sent Bitcoin skyrocketing to a new all-time high above…

Today, yet another Bitcoin (CCC:BTC-USD) exchange-traded fund (ETF) has hit the market. The Valkyrie Bitcoin Strategy ETF (NASDAQ:BTF) began trading today after receiving its blessing from the Securities and Exchange Commission (SEC) earlier this week. Like its peer, the ProShares Bitcoin Strategy ETF (NYSE:BITO), this ETF tracks Bitcoin futures, rather than the spot price of…

Despite reaching its all-time high price yesterday following the historic launch of the ProShares Bitcoin Strategy ETF (NYSE:BITO), Bitcoin (CCC:BTC-USD) has fallen today. Ethereum (CCC:ETH-USD) is still in the green, but both Binance Coin (CCC:BNB-USD) and Cardano (CCC:ADA-USD) are down for the both the day and the week. While some of the biggest names in…

Since this week began, we’ve seen cryptocurrency investing fundamentally transformed through the launch of ProShares Bitcoin Strategy ETF (NYSE:BITO), the first of its kind. Wall Street finally has a way to cash in on the Bitcoin boom while bypassing the volatility that has caused previous investors to shy away from it. Other Bitcoin (CCC:BTC-USD) ETFs (exchange-traded funds)…

This week has witnessed cryptocurrency history with the launch of the first Bitcoin (CCC:BTC-USD) exchange-traded fund (ETF). The ProShares Bitcoin Strategy ETF (NYSE:BITO) has given Wall Street the opportunity to gain exposure to the crypto without the risk that can come from holding it. This news has sent Bitcoin shooting up, leading to it hitting an…

Today marks a real milestone for crypto fans. With the launch of the ProShares Bitcoin Strategy ETF (NYSE:BITO) investors are finally able to invest in Bitcoin (CCC:BTC-USD) futures through an exchange-traded fund. Perhaps more importantly, the debut of the BITO ETF suggests that more Bitcoin ETFs could be on their way. Source: Momentum Fotograh /…

Energous (NASDAQ:WATT) stock is getting a boost on Tuesday after announcing approval from the U.S. Federal Communications Commission (FCC) for its wireless power technology. Source: Michael Vi / Shutterstock.com This covers the company’s 900MHz 1W Active Energy Harvesting transmitter technology. The approval from the FCC allows for wireless power transmission at any range. This opens…

Atea Pharmaceuticals (NASDAQ:AVIR) stock is on the move Tuesday after providing an update from its Phase 2 Moonsong clinical trial update. Source: Shutterstock The Moonsong trial was evaluating the effectiveness of AT-527 in reducing viral infection from Covid-19 in the outpatient setting. Unfortunately for AVIR stock, the results didn’t have it meeting its primary endpoint…